Homeward
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward announced $120M in Series D financing on October 1, 2026. Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Round details
The financing includes backing from Saluda Grade, Continental General Insurance Company, Citi Ventures, Magnetar, Harmony Partners, Norwest, Adams Street Partners, LiveOak Ventures. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $120M
- Headquarters: Austin, TX
How the company plans to use the capital
Homeward said the new capital, including the Series D equity and the debt facilities, will expand its cash offer and bridge financing solutions, enhance the technology behind its integrated home buying and selling platform, and accelerate growth across the 48 contiguous states. The company said the $330 million asset-backed debt facility will be used to fund more home transactions.
Why this matters for GTM teams
The financing shows investor backing for cash offer and bridge financing tools that, according to the company, aim to give buyers and sellers greater certainty during home transactions.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Homeward Series D announcement.
Company Info
Investors (8)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free